新型腺病毒疫苗载体缺乏与血小板因子4的血栓相关相互作用
Erwan Sallard1, Daniel Pembaur2, Matias Ciancaglini3
1Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, 58453 Witten, Germany.
研究人员发现了新的腺病毒载体 (ADS),它们不与血小板因子4 (PF4) 结合,从而降低了血栓形成的风险. 这些安全有效的Ad34和修改的Ad5载体对未来的疫苗开发有很大的前景.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 针对COVID-19的腺病毒载体疫苗 (AstraZeneca,Janssen) 与罕见的血栓形成事件有关.
- 血栓形成可能是由载体与血小板因子4 (PF4) 结合引发的.
研究的目的:
- 选腺病毒 (ADS) 以减少与PF4的结合.
- 为了确定更安全的腺病毒载体用于临床应用.
主要方法:
- 选了50种天然和改性腺病毒以检测PF4结合.
- 测试了PF4结合对Ad5感染性和热带性的影响.
- 评估了HVR1被删除的Ad5和Ad34载体作为小鼠疫苗候选物.
主要成果:
- Ad34,Ad80和修改的Ad5载体 (删除/屏蔽的HVR1) 显示没有PF4结合.
- PF4的相互作用显著改变了细胞中的Ad5感染性和热带性.
- 在小鼠中,HVR1删除的Ad5和Ad34载体诱导了强大的细胞免疫反应.
结论:
- 由于缺乏PF4结合,Ad34和修改的Ad5载体是有希望的候选者.
- 这些载体可能为疫苗开发提供了更好的安全概况.
- PF4的相互作用可以影响腺病毒载体的热带性和传染性.
更多相关视频
11:06Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
08:14Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
Published on: October 26, 2018
相关概念视频
Cross-reactivity
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Hepatitis
